poisar

Stocks · News reference

Immatics Presents Clinical Activity of IMA402 and IMA203CD8 at ESMO 2026

Fiscal.ai

Immatics reported positive clinical data for its PRAME-targeting therapies, IMA402 and IMA203CD8, during oral presentations at the 2026 ESMO Annual Meeting.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncImmatics N.V.

    Immatics Announces Third Quarter 2026 Financial Results and Business Update

    Immatics reported Q3 2026 financial results with cash position of $536.3 million and announced enrollment progress in the Phase 3 SUPRAME trial for anzu-cel (IMA203) in advanced melanoma, with topline data expected in H1 2027. Updated clinical data presented at ESMO Congress 2026 showed IMA203CD8 achieved 55% cORR in gynecologic cancers and IMA402 bispecific demonstrated 32% cORR in PRAME-high melanoma with 91% 1-year OS rate. The company continues advancing its PRAME-targeted cell therapy and bispecific programs across multiple cancer indications.